Novo Nordisk's sales growth will be negatively impacted in 2022

The pharmaceutical company's expectations for the consequences of the new Chinese procurement model for insulin have been released, and they are not good news for the firm.
Photo: Novo Nordisk Pharmatech/PR
Photo: Novo Nordisk Pharmatech/PR
by marketwire, translated by daniel pedersen

Novo Nordisk is predicting that global sales growth will be negatively impacted by 3 percent in 2022, it reports in a press release on Friday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading